Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC
2021 · Journal of Thoracic Oncology · 31 citations
https://doi.org/10.1016/j.jtho.2021.03.011
S
Shamilene Sivagnanam
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
171
Papers
2.1K
Citations
17
h-index
22
i10-index
Shamilene Sivagnanam is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Pancreatic and Hepatic Oncology Research & Cancer Cells and Metastasis. The author has an h-index of 17, co-authored 146 publications.
ORCID: 0000-0001-5966-1522Papers by this author
worksOngoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer
2025 · Nature Cancer · 24 citations
https://doi.org/10.1038/s43018-024-00881-3
Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
2025 · Breast Cancer Research · 4 citations
https://doi.org/10.1186/s13058-025-01964-4
Supplementary Table S1 from Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer
2024 · 1 citations
https://doi.org/10.1158/2326-6066.25736192.v1
Supplementary Figure 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
2024 · 0 citations
https://doi.org/10.1158/1078-0432.25112195
Supplementary Figure 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
2024 · 0 citations
https://doi.org/10.1158/1078-0432.25112192
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat